sgp130 in Chronic Human Liver Disease

Free University of Brussels (ULB)

Status: Completed

Conditions: Alcoholic Liver Disease; Chronic Hepatitis C Virus Infection

Study type: Observational

Funder types: Other

Identifiers

NCT00770198

AL-gp130

Details and patient eligibility

About

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Full description

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

Enrollment: 129 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Alcohol excess intake and suspected liver disease
• Alcohol excess intake and clinical liver cirrhosis
• chronic hepatitis C virus infection and suspected liver disease
• chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion criteria

• other (superimposed) liver disease

Trial design

129 participants in 2 patient groups

alcoholic liver disease

Description:

alcoholic liver disease patients undergoing a transjugular liver biospy in our institution

chronic HCV hepatitis

Description:

chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution